The discussion will be moderated by Laura Batchelor, Co-Chair of the Chamber's Healthcare Committee, and Managing Partner at FIPRA Public Affairs.

Why we’re co-hosting this

• Global leadership in pharma and biotech - Determining the priorities of the next Parliament and Commission in supporting the competitiveness and open strategic autonomy of the European biotech sector.
• Biotech as a critical technology - Recognition of Biotech and Biomanufacturing as a critical sector.
• Impact of the GPL on Europe’s Innovation Ecosystem - The General Pharmaceutical Legislation (GPL) is a once in a generation opportunity to update the regulatory framework, optimising conditions for R&D, and improving patients access to medicines across Europe. 
• Charles River Associates report - Ensuring a reliable IP system and adequate funding mechanisms for biotech SMEs will be crucial for the European healthcare ecosystem and its competitiveness.

Background

Mario Draghi's report on European competitiveness marks a pivotal moment for strategic realignment. The Charles River Associates report warns that proposed GPL changes could introduce greater uncertainty for biotech companies, particularly affecting SMEs essential for discovering new treatments and technologies. In response, the European Commission has initiated several measures, such as the "EU Biotech Hub" and a potential "EU Biotech Act". Yet the urgency for a coherent strategy to ensure Europe's strategic autonomy and competitiveness remains. 

If you have any questions or would like to join online, please contact lauren.dishman@britcham.eu.